< Back to Physicians
Jennifer Gile, MD | Medical Oncologist and Hematologist at WVCI Eugene, OR

Jennifer Gile, MD

Medical Oncologist, Hematologist

Jennifer Gile, MD | Medical Oncologist and Hematologist at WVCI Eugene, OR

Request an Appointment

Primary Location

Eugene
520 Country Club Road
Eugene, Oregon 97401
View Eugene Location

Phone: 541-683-5001
Fax: 541-683-1422

Patient Care Philosophy

Thoughtful and science-driven, Dr. Jennifer Gile provides personalized cancer care informed by rigorous clinical research and guided by each patient’s individual goals and choices.

“I’ve always loved science, but I realized early on that I couldn’t stay in a lab—I needed to work with people. Oncology allows me to engage with the science while building meaningful relationships with my patients.”

Dr. Gile has a particular interest in blood cancers, especially lymphoma, drawn by both personal experiences and the remarkable progress in treatment options over the past decade.

She is a strong advocate for shared decision-making and believes in building trust from the very first visit.

“I spend the time needed to truly understand my patients—their goals, their families, their circumstances—so that every treatment plan is built on a foundation of trust and respect.”

 

Personal Information

Originally from the Pacific Northwest, Dr. Gile is excited to serve the Eugene community, bringing expertise from her training at Mayo Clinic to a more personal, accessible setting.

Outside of work, she enjoys spending time with her husband and young son, exploring Oregon’s natural beauty. Whether hiking local trails, painting, reading mystery novels, or playing on the coast, she finds joy outdoors and the simple moments of family life.

 

Board Certifications

Hematology/Oncology board eligible

Special Interest

Fellowship

Mayo Clinic School of Graduate Medical Education - Rochester MN

Residency

Mayo Clinic School of Graduate Medical Education - Rochester MN

Medical School

University of Colorado School of Medicine - Aurora, CO

Additional Information

Lane County Medical Society [membership pending]

Davison J, Kan J, Gile J, Patgunarajah U, Degenhardt J, Go R, Abeykoon JP. Babesiosis-induced warm autoimmune hemolytic anemia, from infection to hemolysis: a case report. J Med Case Rep. 2025 Aug 11;19(1):400. doi: 10.1186/s13256-025-05466-x. PMID: 40790611; PMCID: PMC12337370.

Gile JJ, Mondello P, Wang Z, Li Y, Bansal R, Gandhi S, Zhang H, Babadi E, Martinez K, McCoy G, Shao Z, Regan K, Hathcock MA, Wang P, Wang J, Al Saleh AS, Ruan G, Ansell SM, Villasboas-Bisneto JC, Khurana A, Durani U, Wang Y, Hampel PJ, Rosenthal A, Munoz J, Merono E, Castro Januario E, Murthy HS, Kharfan-Dabaja M, Kenderian SS, Kim JJ, Shen R, Mattie M, Lin Y, Witzig TE. Hypomagnesemia in lymphoma patients receiving CAR T therapy correlates with immune dysfunction and decreased survival. Experimental Hematology and Oncology 2025 Apr 30;14(1):63. doi: 10.1186/s40164-025-00623-w. PMID: 40307941; PMCID: PMC12044716.

Gairing SJ, Mildenberg P, Gile JJ, et al. - Evaluation of prognostic scores in HCC patients undergoing 1L immunotherapy with atezolizumab and bevacizumab – development and validation of the CABLE score. Journal of Hepatology Rep. 2024 Dec 5;7(3):101295. doi: 10.1016/j.jhepr.2024.101295. PMID: 40059970; PMCID: PMC11889551.

Marell P, Kournoutas I, Gile JJ, Peersen A, Shah P, Babiker H, Kankeu LF, Washburn L, Graham R, Truty M, Starlinger P, Halfdanarson T, Jin Z, Jatoi A, McWilliams R, Borad M, Bekaii-Saab TS, Mahipal A, Ou FS, Tran NH. Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience. Oncologist. 2024 Dec 14:oyae342. doi: 10.1093/oncolo/oyae342. Epub ahead of print. PMID: 39674576.

Gow-Lee V, Abu Saleh OM, Harris CE, Gile JJ, Akhiyat N, Chesdachai S. Outcomes of Invasive Fungal Infections Treated with Isavuconazole: A Retrospective Review. Pathogens. 2024 Oct 11;13(10):886. doi: 10.3390/pathogens13100886. PMID: 39452757; PMCID: PMC11510498.

Gile JJ, Maurer M, Ruan GJ, Abeykoon JP, Heimgartner JR, Baumann NA, McMahon M, Lin Y, Witzig TE. Low magnesium levels and prognosis in newly diagnosed diffuse large B-cell lymphoma. Oncologist. 2024 Dec 6;29(12):e1779-e1782. doi: 10.1093/oncolo/oyae255. PMID: 39418117; PMCID: PMC11630732.

Storandt MH, Zemla TJ, Patell K, Naleid N, Gile JJ, Tran NH, Chakrabarti S, Jin Z, Borad M, Mahipal A. Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study, The Oncologist, 2024; https://doi.org/10.1093/oncolo/oyae142.

Bock AM, Gile JJ, Larson MC, Poonsombudlert K, Tawfiq RK, Maliske S, Maurer MJ, Kabat BF, Paludo J, Inwards DJ, Ayyappan S, Link BK, Ansell SM, Habermann TM, Witzig TE, Nowakowski GS, Cerhan JR, Farooq U, Wang Y. Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study. Blood Cancer J. 2023 Nov 13;13(1):169. doi: 10.1038/s41408-023-00942-3. PMID: 37957158; PMCID: PMC10643454.

Palmer ME, Gile JJ, Storandt MH, Jin Z, Zemla TJ, Tran NH, Mahipal A. Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib following Immunotherapy: A Real World Evidence Study. Cancers (Basel). 2023 Oct 6;15(19):4867. doi: 10.3390/cancers15194867. PMID: 37835561; PMCID: PMC10571707.

Ng CT, Gonzalez Bonilla HM, Chang I, Aung MT, Gile JJ, Pereira NL, Villasboas Bisneto JC, Johnston PB, Villarraga HR, Rodriguez-Porcel MG, Lin G, Lin Y, Herrmann J. CAR-T Therapy in Lymphoma Patients With Coexisting Cardiomyopathy or Cardiac Lymphomatous Involvement. JACC Case Rep. 2023 Apr 21;15:101840. doi: 10.1016/j.jaccas.2023.101840. PMID: 37283829; PMCID: PMC10240233.

Gile JJ, McGarrah PW, Leventakos K, Sonbol MB, Starr JS, Eiring RA, Hobday TJ, Halfdanarson TR. Efficacy of checkpoint inhibitors in combination with chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinoma. J Neuroendocrinol. 2023 May;35(5):e13283. doi: 10.1111/jne.13283. Epub 2023 May 25. PMID: 37229903

Marell PS, Diehn FE, Gile JJ. Acute Pontine Osmotic Demyelination Syndrome at Presentation of Lymphoma in Association With Hypoalbuminemia. Mayo Clin Proc. 2023 Apr;98(4):507-508. doi: 10.1016/j.mayocp.2022.11.016. PMID: 37019512.

Storandt MH, Gile JJ, Palmer ME, Zemla TJ, Ahn DH, Bekaii-Saab TS, Jin Z, Tran NH, Mahipal A. Cabozantinib following immunotherapy in patients with advanced hepatocellular carcinoma. Cancers. 2022 Oct 22;14(21):5173. doi: 10.3390/cancers14215173. PMID: 36358592; PMCID: PMC9657200.

Gile, JJ, Wookey, V., Zemla, T.J. et al. Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma. Targ Oncol (2022). https://doi.org/10.1007/s11523-022-00914-w

Gile J, Jatoi A, Wee Ma W, Borad M, Tran NH. Reply to A. Rizzo et al. JCO Precis Oncol. 2022 Mar;6:e2200061. doi: 10.1200/PO.22.00061. PMID: 35294225.

Gile JJ, Ou FS, Mahipal A, Larson JJ, Mody K, Jin Z, Hubbard J, Halfdanarson T, Alberts SR, Jatoi A, McWilliams RR, Ma WW, Ilyas S, Smoot R, Roberts L, Gores G, Borad M, Bekaii-Saab TS, Tran NH. FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precis Oncol. 2021 Jul 28;5:PO.21.00064. doi: 10.1200/PO.21.00064. PMID: 34778691; PMCID: PMC8575436.

Gile JJ, Liu AJ, McGarrah PW, Eiring RA, Hobday TJ, Starr JS, Sonbol MB, Halfdanarson TR. Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms: Mayo Clinic Experience. Pancreas. 2021 Apr 1;50(4):500-505. doi: 10.1097/MPA.0000000000001794. PMID: 33939660.

Gile JJ, Lopez CL, Ruan GJ, Hathcock MA, Abeykoon JP, Heimgartner JR, Baumann NA, McMahon MM, Micallef IN, Johnston PB, Bisneto JCV, Porrata LF, Paludo J, Ansell SM, Hogan WJ, Witzig TE. Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure. Blood Cancer J. 2021 Mar 26;11(3):65. doi: 10.1038/s41408-021-00452-0. PMID: 33771971; PMCID: PMC7998023.

Gile JJ, Sara JDS, Mueller MR. Systemic lupus erythematosus multiorgan flare with qwith quiescent serologic markers. BMJ Case Rep. 2021 Mar 2;14(3):e239048. doi: 10.1136/bcr-2020-239048. PMID: 33653839; PMCID: PMC7929838.

Gile JJ, Satterfield BA, Leasure EL. 37-Year-Old Woman With Bilateral Lower Extremity Edema, Proteinuria, and Microscopic Hematuria. Mayo Clin Proc. 2020 Aug;95(8):e81-e86. doi: 10.1016/j.mayocp.2019.12.035. PMID: 32753162.

Gile J, Ruan G, Abeykoon J, McMahon MM, Macon WR, Witzig TE. Hypomagnesemia is associated with an increased risk of early clinical failure in patients with Burkitt lymphoma. Leuk Lymphoma. 2020 Sep; 61(9):2274-2276. doi: 10.1080/10428194.2020.1759056. Epub 2020 May 2. PMID: 32364025.

Gile J, Oyama Y, Shuff S, Eckle T. A Role for the Adenosine ADORA2B Receptor in Midazolam Induced Cognitive Dysfunction. Curr Pharm Des. 2020;26(34):4330-4337. doi: 10.2174/1381612826666200415171622. PMID: 32294028; PMCID: PMC7572481.

Gile J, Ruan G, Abeykoon J, McMahon MM, Witzig T. Magnesium: The overlooked electrolyte in blood cancers? Blood Rev. 2020 Nov;44:100676. doi:
10.1016/j.blre.2020.100676. Epub 2020 Mar 27. PMID: 32229066.

Oyama Y, Bartman CM, Gile J, Sehrt D, Eckle T. The Circadian PER2 Enhancer Nobiletin Reverses the Deleterious Effects of Midazolam in Myocardial Ischemia and Reperfusion Injury. Curr Pharm Des. 2018;24(28):3376-3383. doi: 10.2174/1381612824666180924102530. PMID: 30246635; PMCID: PMC6318050.

Gile J, Scott B, Eckle T. The Period 2 Enhancer Nobiletin as Novel Therapy in Murine Models of Circadian Disruption Resembling Delirium. Crit Care Med. 2018 Jun; 46(6):e600-e608. doi: 10.1097/CCM.0000000000003077. PMID: 29489460; PMCID: PMC5953804.

Hsu YA, Gile JJ, Perez JG, Morton G, Ben-Hamo M, Turner EE, de la Iglesia HO. The Dorsal Medial Habenula Minimally Impacts Circadian Regulation of Locomotor Activity and Sleep. J Biol Rhythms. 2017 Oct;32(5):444-455. doi: 10.1177/0748730417730169. Epub 2017 Sep 27. PMID: 28954569; PMCID: PMC5882496.

Oyama Y, Bartman CM, Gile J, Eckle T. Circadian MicroRNAs in Cardioprotection. Curr Pharm Des. 2017;23(25):3723-3730. doi: 10.2174/1381612823666170707165319. PMID: 28699517; PMCID: PMC5638700.

Gile J, Eckle T. ADORA2b Signaling in Cardioprotection. J Nat Sci. 2016;2(10):e222. PMID: 27747290; PMCID: PMC5061046.

Kalume F, Oakley JC, Westenbroek RE, Gile J, de la Iglesia HO, Scheuer T, Catterall WA. Sleep impairment and reduced interneuron excitability in a mouse model of Dravet Syndrome. Neurobiol Dis. 2015 May;77:141-54. doi: 10.1016/j.nbd.2015.02.016. Epub 2015 Mar 10. PMID: 25766678; PMCID: PMC4402280.